<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463293</url>
  </required_header>
  <id_info>
    <org_study_id>11-SUS-02-FON-02</org_study_id>
    <nct_id>NCT01463293</nct_id>
  </id_info>
  <brief_title>B. Lactis HN019 for Functional Constipation</brief_title>
  <acronym>CTT</acronym>
  <official_title>Effects of 4-week Bifidobacterium Lactis HN019 Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fonterra Research Centre</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DuPont Nutrition and Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fonterra Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of 4-week probiotic supplementation on whole gut
      transit time and gastrointestinal symptoms in adults with functional constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, double-blind, randomized, placebo-controlled clinical trial will
      investigate the effects of 4-week B. lactis HN019 supplementation on whole gut transit time
      and gastrointestinal symptoms in adults with functional constipation. Participants who meet
      all study entry criteria will enter a 2-week run-in period. Following successful completion
      of the run-in period, subjects will be randomized to 4-week supplementation with B. lactis
      HN019 (10 billion cfu), B. lactis HN019 (1 billion cfu), or placebo. The primary outcome of
      whole gut transit time will be evaluated with abdominal x-rays on days 0 and 28. Secondary
      outcomes include IBS-specific questionnaires (administered on days 0 and 28); abdominal pain
      severity, bowel movement frequency, stool consistency, and adverse events (evaluated daily
      throughout the study); and overall product satisfaction (evaluated at day 28). Physical
      activity questionnaires and 24-hour food recalls will be completed periodically during the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Gut Transit Time</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary endpoint of this clinical trial is whole gut transit time, which will be assessed using abdominal x-rays on days 0 and 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The PAC-SYM tool asks 12 questions on the symptoms of constipation. Subjects will complete the PAC-SYM at days 0 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation QoL (PAC-QoL)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The PAC-QoL is a 28-question survey that asks questions on their quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Function Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Bowel Function Index is a 3-question tool that asks subjects if they have experienced adequate relief of constipation symptoms over the past week. The Bowel Function Index will be completed at days 0 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Relief of Constipation (Yes/no)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adequate relief of constipation (yes/no) This (yes/no) questionnaire will be completed at days 0 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Movement Frequency</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjects will record the number of defecations per day in a diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Product Satisfaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of the supplementation period, subjects will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>4 weeks</time_frame>
    <description>All adverse events, regardless of relationship with investigational product, will be reported during the 4-week follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>High-dose probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 10 billion cfu B. lactis HN019</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 1 billion cfu B. lactis HN019</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B. lactis HN019</intervention_name>
    <description>Capsule containing 10 billion cfu B. lactis HN019 once a day</description>
    <arm_group_label>High-dose probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B. lactis HN019</intervention_name>
    <description>Capsule containing 1 billion cfu B. lactis HN019 once a day</description>
    <arm_group_label>Low dose probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule containing no probiotic once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Body mass index between 18.5 and 34.9 kg/m2

          -  Self-reported unsatisfactory defecation due to infrequent stools and/or difficult
             stool passage, which includes at least one of the following: symptoms of straining,
             difficulty expelling stool, a sense of incomplete evacuation, hard or lumpy stools,
             prolonged time to stool, or a need for manual maneuvers to pass stool.

          -  Estimated stool consistency &lt; 4.0 on BSSF (self-reported at screening) within the past
             month prior to enrollment.

          -  Ability of the participant (in the investigator's opinion) to comprehend the full
             nature and purpose of the study including possible risks and side effects

          -  Consent to the study and willing to comply with study product and methods

        Exclusion Criteria:

          -  Major gastrointestinal complication (e.g. Crohn's disease, ulcer)

          -  Prior abdominal surgery that, in the opinion of the investigator, may present a risk
             for the subject or confound study results

          -  Clinically significant underlying systemic illness that may preclude the subject's
             ability to complete the trial or that may confound the study outcomes (e.g. bowel
             cancer, prostate cancer, terminal illness)

          -  Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2
             weeks of screening and throughout the trial other than the provided study products

          -  Non-laxative constipation medication use within 2 weeks of screening, laxative use
             within 48 hours of screening (rescue medication allowed for intolerable symptoms
             during study)

          -  Daily use of anticholinergic agents, opioid analgesics, calcium supplements,
             calcium-channel blockers, and NSAIDs

          -  Anticipated major dietary or exercise changes during the study

          -  Systemic steroid use

          -  Eating disorder

          -  Contraindication to dairy products (e.g., intolerance to lactose or any substance in
             the study product)

          -  History of alcohol, drug, or medication abuse

          -  Pregnant or lactating female, or pregnancy planned during study period

          -  Participation in another study with any investigational product within 30 days of
             screening

          -  Investigator believes that the participant may be uncooperative and/or noncompliant
             and should therefore not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Digestive Care, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arrowhead Family Health Center</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnamics, Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive &amp; Liver Disease Specialists</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StayWell Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sprim ALS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Trials South Main</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2014</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>probiotic</keyword>
  <keyword>functional constipation</keyword>
  <keyword>IBS-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-dose Probiotic</title>
          <description>Capsule containing 10 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 10 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Probiotic</title>
          <description>Capsule containing 1 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 1 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo capsule
Placebo: Capsule containing no probiotic once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Probiotic</title>
          <description>Capsule containing 10 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 10 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Probiotic</title>
          <description>Capsule containing 1 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 1 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo capsule
Placebo: Capsule containing no probiotic once a day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="12.1"/>
                    <measurement group_id="B2" value="42.9" spread="12.0"/>
                    <measurement group_id="B3" value="41.1" spread="12.6"/>
                    <measurement group_id="B4" value="41.8" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American, Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height, M</title>
          <units>M</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.66" spread="0.12"/>
                    <measurement group_id="B2" value="1.68" spread="0.09"/>
                    <measurement group_id="B3" value="1.68" spread="0.10"/>
                    <measurement group_id="B4" value="1.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight, Kg</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="15.2"/>
                    <measurement group_id="B2" value="77.5" spread="15.9"/>
                    <measurement group_id="B3" value="74.3" spread="14.9"/>
                    <measurement group_id="B4" value="75.6" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="4.2"/>
                    <measurement group_id="B2" value="27.4" spread="4.4"/>
                    <measurement group_id="B3" value="26.6" spread="4.7"/>
                    <measurement group_id="B4" value="27.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Whole Gut Transit Time</title>
        <description>The primary endpoint of this clinical trial is whole gut transit time, which will be assessed using abdominal x-rays on days 0 and 28</description>
        <time_frame>4 weeks</time_frame>
        <population>Only 39 out of the 224 enrolled subjects consumed the radio-opaque markers in line with the protocol. Because of the substantial number of protocol deviations and the lack of sufficient evaluable subjects, no further analyses of the study data were performed. The study appears not to have yielded evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Probiotic</title>
            <description>Capsule containing 10 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 10 billion cfu B. lactis HN019 once a day</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Probiotic</title>
            <description>Capsule containing 1 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 1 billion cfu B. lactis HN019 once a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule
Placebo: Capsule containing no probiotic once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Gut Transit Time</title>
          <description>The primary endpoint of this clinical trial is whole gut transit time, which will be assessed using abdominal x-rays on days 0 and 28</description>
          <population>Only 39 out of the 224 enrolled subjects consumed the radio-opaque markers in line with the protocol. Because of the substantial number of protocol deviations and the lack of sufficient evaluable subjects, no further analyses of the study data were performed. The study appears not to have yielded evaluable data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Constipation Symptoms (PAC-SYM)</title>
        <description>The PAC-SYM tool asks 12 questions on the symptoms of constipation. Subjects will complete the PAC-SYM at days 0 and 28.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Constipation QoL (PAC-QoL)</title>
        <description>The PAC-QoL is a 28-question survey that asks questions on their quality of life.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Function Index</title>
        <description>The Bowel Function Index is a 3-question tool that asks subjects if they have experienced adequate relief of constipation symptoms over the past week. The Bowel Function Index will be completed at days 0 and 28.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequate Relief of Constipation (Yes/no)</title>
        <description>Adequate relief of constipation (yes/no) This (yes/no) questionnaire will be completed at days 0 and 28.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Movement Frequency</title>
        <description>Subjects will record the number of defecations per day in a diary.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency</title>
        <description>Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Product Satisfaction</title>
        <description>At the end of the supplementation period, subjects will be asked to rate their overall satisfaction with the study productâ€™s ability to relieve their constipation symptoms on a 5-point ordinal scale</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Frequency</title>
        <description>All adverse events, regardless of relationship with investigational product, will be reported during the 4-week follow-up period.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High-dose Probiotic</title>
          <description>Capsule containing 10 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 10 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Probiotic</title>
          <description>Capsule containing 1 billion cfu B. lactis HN019
B. lactis HN019: Capsule containing 1 billion cfu B. lactis HN019 once a day</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo capsule
Placebo: Capsule containing no probiotic once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respriatory symptoms</sub_title>
                <description>Upper respiratory tract infection, common cold, bronchitis</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A substantial number of protocol violations occurred for the primary end-point. Only 39 out of 224 subjects consumed sufficent radio-opaque markers for baseline and post-intervention transit time.Therefore, the study failed to yield evaluable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr James Dekker</name_or_title>
      <organization>Fonterra Research Centre</organization>
      <phone>+64 6 350 6323</phone>
      <email>james.dekker@fonterra.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

